Methysergide-Induced Retroperitoneal Fibrosis: Successful Outcome and Two New Laboratory Features
- 31 December 1997
- journal article
- case report
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 72 (12) , 1148-1150
- https://doi.org/10.4065/72.12.1148
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Resistance to activated protein C activity of an anti‐/2 ‐glycoprotein I antibody in the presence of β‐glycoprotein IBritish Journal of Haematology, 1995
- Evans’ syndrome, myelofibrosis and systemic lupus erythematosus: role of procollagens in myelofibrosisPathology, 1995
- Prevalence of beta 2-glycoprotein I antibody in systemic lupus erythematosus patients with beta 2-glycoprotein I dependent antiphospholipid antibodies.Annals of the Rheumatic Diseases, 1995
- Iliocaval complications of retroperitoneal fibrosisThe American Journal of Surgery, 1994
- Mutation in blood coagulation factor V associated with resistance to activated protein CNature, 1994
- Inherited resistance to activated protein C iscorrected by anticoagulant cofactor activity found to be a property of factorV.Proceedings of the National Academy of Sciences, 1994
- Association of anti-β2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosusThe American Journal of Medicine, 1992
- Retroperitoneal fibrosis accompanying immune thrombocytopeniaAmerican Journal of Hematology, 1991
- Increased serum procollagen III aminoterminal peptide in myelofibrosisAmerican Journal of Hematology, 1983
- Fibrotic Disorders Associated with Methysergide Therapy for HeadacheNew England Journal of Medicine, 1966